Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: f9204393752937fe34d399eb93f2c124696d3ea6
First added on: Feb 01, 2023